Literature DB >> 7562908

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

A M Thompson1, A J Bridges, D W Fry, A J Kraker, W A Denny.   

Abstract

The synthesis of 7-aminopyrido[4,3-d]pyrimidines bearing aromatic side chains at the 4-position is reported. These compounds are shown to be a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Structure-activity relationships (SARs) for substitution in both 4-(phenylamino)- and 4-[(phenylmethyl)amino] side chains were determined, using a series of substituents (NO2, Br, CF3, OMe, NH2, and NMe2) selected primarily for their wide range of electronic properties. In the phenylamino series, 3-substituted derivatives were more potent than the corresponding 2- and 4-substituted analogues. For the 3-substituted compounds, activity was favored by electron withdrawal, in a relationship which could be quantified, with the 3-Br being the most potent compound (IC50 = 0.01 microM compared with IC50 = 0.34 microM for the unsubstituted side chain derivative). No such correlation was apparent for the 2- or 4-substituent, although Br was still the best substituent. In contrast, in the 4-[(phenylmethyl)amino] series, substitution of the side chain was not beneficial. For the 4-(phenylamino) series, the substituent SARs are broadly similar to that found previously for 4-(phenylamino)quinazolines. These results suggest that side chain SARs may be broadly invariant over a range of different chromophores, with the side chain of choice for optimization of EGFR inhibitory activity being 4-[(3-bromophenyl)amino].

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562908     DOI: 10.1021/jm00019a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Sonochemical synthesis of pyrido[2,3-d:6,5-d']-dipyrimidines catalyzed by [HNMP]+[HSO4]- and their antimicrobial activity studies.

Authors:  Hossein Naeimi; Asieh Didar; Zahra Rashid; Zohreh Zahraie
Journal:  J Antibiot (Tokyo)       Date:  2017-04-26       Impact factor: 2.649

2.  In silico QSAR studies of anilinoquinolines as EGFR inhibitors.

Authors:  Farhan Ahmad Pasha; Muhammad Muddassar; Anil Kumar Srivastava; Seung Joo Cho
Journal:  J Mol Model       Date:  2009-07-10       Impact factor: 1.810

Review 3.  HER-2-directed, small-molecule antagonists.

Authors:  Michelle Arkin; Mark M Moasser
Journal:  Curr Opin Investig Drugs       Date:  2008-12

4.  Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.

Authors:  Hongying Du; Zhide Hu; Andrea Bazzoli; Yang Zhang
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

5.  2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors.

Authors:  Manman Zhao; Lin Wang; Linfeng Zheng; Mengying Zhang; Chun Qiu; Yuhui Zhang; Dongshu Du; Bing Niu
Journal:  Biomed Res Int       Date:  2017-05-29       Impact factor: 3.411

6.  Synthesis and cytotoxic evaluation of some novel 3-[2-(2-phenyl-thiazol-4-yl)-ethyl]-3H-pyrido[2,3-d]pyrimidin-4-one derivatives.

Authors:  Marzieh Rahmani Khajouei; Ghadamali Khodarahmi; Aram Ghaderi
Journal:  Res Pharm Sci       Date:  2021-08-19

7.  QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.

Authors:  Jagat Singh Chauhan; Sandeep Kumar Dhanda; Deepak Singla; Subhash M Agarwal; Gajendra P S Raghava
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

8.  Synthesis, Antitumor Evaluation and Molecular Docking of New Morpholine Based Heterocycles.

Authors:  Zeinab A Muhammad; Mastoura M Edrees; Rasha A M Faty; Sobhi M Gomha; Seham S Alterary; Yahia N Mabkhot
Journal:  Molecules       Date:  2017-07-20       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.